Somanetics starts shipment of new oximeter:
This article was originally published in Clinica
Somanetics has commenced US delivery of its next-generation cerebral oximeter monitoring system. The INVOS claims to be able to monitor oxygen on both sides of the brain simultaneously and will be available for children and new-born babies when these uses have been approved. The company is marketing the product for use in operating theatres as well as post-anaesthetic and intensive care.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.